冠状动脉支架内慢性完全闭塞病变介入治疗5年预后研究

目的:评价冠状动脉支架内慢性完全闭塞（IS-CTO）病变经皮冠状动脉介入治疗（PCI）的安全性及远期疗效。方法:本研究为回顾性研究,选取2010年1月1日至2013年12月31日于中国医学科学院阜外医院接受PCI的冠状动脉慢性完全闭塞（CTO）病变患者。将符合纳排标准的IS-CTO患者212例纳入IS-CTO组,以1∶...     

药物洗脱支架对开通冠状动脉慢性完全闭塞病变患者预后的影响

目的:评价经皮冠状动脉介入治疗(PCI)成功开通冠状动脉慢性完全闭塞病变(CTO),对患者长期预后的影响。方法:连续选取2010年1月至2012年1月,在首都医科大学附属北京安贞医院心内科一病房,经冠状动脉造影检查证实CTO病变,并PCI试行开通CTO病变患者为研究对象。记录患者临床资料、冠状动脉造影情况、手术并发症及PCI结果,根据手术是否成功分为PCI成功组(n=583)和PCI失败组(n=101)。院外随访入选患者,随访截止至2015年1月。随访主要终点事件为全因死亡率,次要终点事件为非致死性心肌梗死、再次血运重建及总MACE发生率,比较PCI成功组与失败组长期预后的差别。结果:研究共入选CTO患者684例,583例经PCI成功开通并置入药物涂层支架,开通率(85.2%)。随访时间4.6(3,5)年,其中成功开通CTO组失访60例(失访率10.3%),失败组失访10例(失访率9.9%)。校正前PCI成功组总MACE(23.3%vs.48.5%,P0.05)、全因死亡率(5.2%vs.17.8%,P0.05)、TVR率(11.2%vs.21.8%,P0.05)低于失败组,非致死性MI发生率与失败组差异无统计学意义(7.0%vs.8.9%,P0.05)。Cox模型多因素分析显示,PCI成功组总MACE发生率(HR:1.421,95%CI:1.079~1.870)、全因死亡率(HR:0.324,95%CI:0.165~0.637)、TVR率(HR:2.077,95%CI:1.459~2.761)仍明显低于失败组(P0.05)。结论:对慢性闭塞病变行成功的PCI术,可以降低全因死亡率和再次血运重建率,降低MACE的发生率,改善患者长期预后。     

冠状动脉慢性完全闭塞病变患者PCI术预后模型的建立

目的 探讨影响冠状动脉慢性完全闭塞病变PCI术后(CTO-PCI)患者发生主要不良心血管事件(MACE)的独立危险因素,为辅助制定临床决策提供参考依据.方法 回顾性分析1 415例符合冠状动脉慢性完全闭塞病变的PCI术后患者的临床和随访资料.运用R3.6.2和易侕软件对数据建立MFP模型、全因素Cox回归模型(full...     

BridgePoint系统开通冠状动脉慢性完全闭塞病变的临床疗效

目的探讨BridgePoint系统支持下正向内膜下重回真腔技术(ADR)开通冠状动脉慢性完全闭塞病变(CTO)的安全性、有效性和预后。方法连续入选自2016年4月至2018年12月于西京医院接受BridgePoint系统开通CTO病变的患者87例,进行回顾性分析。记录入选患者的一般资料、CTO病变的影像学特征及术中相关参数。观察入选患者的短期预后,包括技术成功(达TIMI 3级血流及残余狭窄<30%)率、手术成功[住院期间无主要不良心血管事件(MACE)发生]率、并发症以及住院期间MACE。MACE包括死亡、再发心肌梗死、靶血管重建(TVR)和心脏压塞等。于出院后30 d及6、12、24和36个月,通过门诊或电话随访入选患者MACE发生情况。结果87例患者中,男性75例(86%),年龄(61±10)岁,J-CTO评分为(2.49±0.52)分。6例患者采用BridgePoint系统直接行ADR术,均成功。81例患者行BridgePoint系统补救性ADR术,其中62例成功,BridgePoint系统ADR术成功率为78.2%(68/87);19例患者于手术失败后通过正向/逆向技术补救,成功9例,失败10例。技术成功率为88.5%(77/87)。冠状动脉穿孔2例(2.3%),1例置入覆膜支架,1例心包填塞后给予心包穿刺;围手术期心肌梗死1例,猝死1例,心脏压塞1例。住院期间入选患者MACE发生率为3.4%(3/87),手术成功率为85.1%(74/87)。手术时间为(175±72)min,对比剂剂量为(449±155)ml。随访17(11,26)个月,86例患者完成了随访,30 d MACE发生率为4.7%(4/86),6个月为10.5%(9/86),17个月为17.4%(15/86)。结论BridgePoint系统开通冠状动脉CTO的成功率较高,安全、可行,临床预后较好。     

冠状动脉慢性完全闭塞病变介入治疗的临床证据解读

近年随着设备和技术的改进及操作经验的不断积累,冠状动脉慢性完全闭塞病变的经皮冠状动脉介入治疗(PCI)发展迅速,但不成功的血运重建增加了心血管事件风险,影响了预后,使得冠状动脉慢性完全闭塞病变仍然是介入心脏病专家面临的最大挑战之一。现通过回顾既往冠状动脉慢性完全闭塞病变行PCI的相关临床证据,分析冠状动脉慢性完全闭塞病变行PCI的获益和风险,以期为临床医生应用PCI治疗冠状动脉慢性完全闭塞病变提供理论基础。     

药物涂层球囊血管成形术与药物洗脱支架置入术治疗冠状动脉慢性完全闭塞病变疗效对比研究

目的 对比药物涂层球囊（DCB）血管成形术与药物洗脱支架（DES）置入术应用于冠状动脉慢性完全闭塞病变（CTO）治疗的临床疗效。方法 选取2020年12月至2021年12月于北部战区总医院心血管内科行冠脉造影显示为CTO病变并成功开通的89例连续入选患者为研究对象,随访期1年,依据2021年DCB亚太专家共识,将治疗方案分为DCB组（n=32）与DES组（n=57）;主要观察终点为1年随访患者靶血管血运重建（TVR）情况;次要终点为患者血管造影行定量冠脉造影检查（QCA）,靶血管的最小管腔直径（MLD）、平均管腔直径（MVD）、参考管腔直径（RFD）以及晚期管腔直径扩大（LLE）等情况;安全性终点包括手术即时安全性、主要心血管不良事件（MACE）发生率、出血学术研究联合会（BARC）出血分级增加率。结果 本研究平均随访时间为（12±3）个月,两组患者术后1年的TVR发生率分别为12.50%、10.53%,两组差异无统计学意义（P>0.05）;安全终点中,两组患者MACE发生率分别为12.50%、12.28%,BRAC出血分级增加率分别为12.50%、14.04%,差异均无统计学意...     

女性患者慢性完全闭塞病变经皮冠状动脉介入治疗的研究进展

慢性完全闭塞病变(chronic total occlusion,CTO)是指冠状动脉的完全闭塞,TIMI血流0级,且闭塞时间≥3个月的病变[1].目前,CTO已成为经皮冠状动脉介入治疗(percuta-neous coronary intervention,PCI)的难点.随着器械更新、技术成熟和研究深入,CTO-P...     

冠状动脉慢性完全闭塞病变研究最新进展

<正>冠状动脉慢性完全闭塞病变(chronic total occlusion,CTO)是指,闭塞时间>3个月的病变。CTO病变约占全部冠状动脉造影的30%以上,目前接受经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)者<8%,仅占全部PCI病例的10%～20%,与非闭塞冠状动脉病变相比,[1-2]     

当代冠状动脉慢性完全闭塞病变介入治疗流程图解读及对比

随着技术、理念的精进及新型器械的出现,冠状动脉慢性完全闭塞(CTO)病变接受经皮冠状动脉介入治疗(PCI)的成功率较前有了很大的提高。全球多个国家、地区陆续形成了各自的手术推荐路径,即流程图。各流程图特点鲜明,有着明显的时代及地区印记,体现出了流程图制定者对CTO-PCI的深刻理解,对全球CTO-PCI的普及与规范起到了积极的推动作用。随着未来学术交流环境更加全球化、规范化,CTO-PCI的技术、理念也必将得以进一步提高。     

冠状动脉介入治疗慢性完全闭塞的研究进展

<正>慢性完全闭塞病变(chronic total occlusion,CTO)在临床实践中并不少见,但只有很少一部分患者接受冠状动脉介入治疗(percutaneous coronary intervention, PCI)。慢性完全闭塞病变的冠状动脉介入治疗(chronic total occlusion percutaneous coronary intervention, CTO-PCI)是目前冠状动脉介入治疗方面仍具挑战性的领域。近一     

The retrograde approach to coronary artery chronic total occlusions: a practical approach

The retrograde approach has revolutionized the treatment of chronic total occlusions. Several retrograde techniques have recently been described. In this article, we present a practical review with step-by-step instructions on the indications for retrograde interventions, equipment and retrograde channel selection, and techniques for retrograde crossing and treatment of chronic total occlusions.     

Use of the Stingray® guidewire and the Venture® catheter for crossing flush coronary chronic total occlusions due to in‐stent restenosis

We report two cases of flush chronic total occlusion due to in‐stent restenosis, in which percutaneous coronary intervention attempts via over‐the‐wire balloons and microcatheters failed to cross the lesion. Using the Venture® catheter for support and the Stingray® guidewire for enhanced penetration capacity, both lesions were successfully crossed and stented. © 2010 Wiley‐Liss, Inc.     

Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.

OBJECTIVES: This study sought to determine the clinical and angiographic outcomes after drug-eluting stent (DES)-supported percutaneous coronary intervention (PCI) for chronic total coronary occlusion (CTO). BACKGROUND: There are few data about the efficacy of DES-supported PCI for CTO. METHODS: All consecutive patients who had a sirolimus-eluting stent or a paclitaxel-eluting stent implanted for CTO from December 2003 to December 2004 were analyzed. Clinical and angiographic outcomes of patients treated with DES were compared with a case-matched control group of patients treated with bare metal stents (BMS) in the 12 months before the routine use of DES. RESULTS: Successful DES-supported PCI was performed in 92 patients and 104 CTO. The case-matched control group consisted of 26 patients and 27 CTO successfully treated with BMS. There were no differences between groups in baseline clinical and angiographic characteristics. Stent length in the DES group was higher as compared with that of BMS group (51+/-28 mm vs. 40+/-19 mm, P=0.073). The 6-month major adverse cardiac event (MACE) rate was lower in the DES group as compared with that of BMS group (9.8% vs. 23%, P=0.072). The angiographic follow-rate was 80% in the DES group and 81% in the BMS group. The 6-month restenosis rate was 19% in the DES group and 45% in the BMS group (P<0.001). By multivariate analysis, it was found that in the DES group, the only predictors of restenosis were stented segment length (OR 1.031, 95% CI 1.01-1.06, P=0.009) and a target vessel reference diameter<2.5 mm (OR 6.48, 95% CI 1.51-27.83, P=0.012), while the only predictor of MACE was stent length (OR 1.04, 95% CI 1.01-1.08, P=0.006). CONCLUSIONS: DES implantation for CTO decreases the risk of mid-term restenosis and MACE. Small vessels and diffuse disease requiring the implantation of multiple stents and very long stents for full coverage of the target lesion are still associated with a relatively high risk of restenosis.     

Initial experience with a dedicated coronary re-entry device for revascularization of chronic total occlusions

Objective : The aim of this registry was to evaluate a new device designed to facilitate antegrade guidewire re‐entry into the true lumen of a chronic total coronary occlusion (CTO) from the adjacent subintimal space. Background : Successful recanalization of CTOs results in clinical improvement in appropriately selected patients. CTO intervention is time‐ and resource‐consuming, and a simplified approach enabling antegrade guidewire re‐entry into the distal true lumen might improve success. Methods : Patients with CTO and ischemia were entered into a prospective registry regardless of lesion characteristics. If wire manipulation resulted in subintimal wire entrapment, a new re‐entry tool (a 2.5‐mm flat subintimal balloon with two exit ports offset by 180°) was used as a platform to attempt guidewire penetration into the distal true lumen. The primary endpoint assessed was successful device‐guided re‐entry. Standard techniques were then utilized to open the CTO. Results : In 40 consecutive CTO lesions attempted, 19 resulted in subintimal wire entrapment (mean occlusion length 44 mm). Sixteen of these 19 were successfully crossed with an antegrade guidewire into the distal true lumen using the new device (84%). One patient with unsuccessful re‐entry was subsequently recanalized with a retrograde technique. All crossed lesions were stented (17/17), resulting in TIMI 3 flow without major complications. Two cases were unsuccessful. One patient had a grade I coronary perforation requiring no treatment. Conclusions : A new device to recanalize CTOs complicated by subintimal wire entrapment can be used successfully by experienced operators. Further study of this coronary re‐entry device is ongoing. © 2011 Wiley Periodicals, Inc.     

Coronary stenting with a balloon-expandable stent after the recanalization of chronic total occlusions

To diminish the restenosis rate after successful recanalization of chronic total coronary occlusion, we have implanted the Palmaz-Schatz stent in 6 patients. All procedures were successfully done without major complications. The angiographic follow-up at 6 months showed restenosis in one asymptomatic patient who had had 2 stents implanted. Five other patients had no evidence of restenosis.     

Elective versus deferred stenting following subintimal recanalization of coronary chronic total occlusions

Subintimal tracking and re‐entry (STAR) technique has been described as a bailout strategy for coronary total occlusion (CTO) recanalization. However, the length of the dissected segment represents a major concern. The aim of this study is, to evaluate whether “deferred” stent implantation may limit the total stent length following STAR recanalization of CTO. All consecutive patients with CTO in a native coronary artery treated by successful STAR technique in our institution were included. In the first period (March 2004–December 2009) all procedures were completed with stent implantation (Elective Stent Group; n = 60). Thereafter (January 2010–June 2012) stent implantation was postponed until a scheduled (within 3 months) angiographic follow‐up (Deferred Stent Group; n = 69). The dissection length was 75 ± 37 mm in the Elective Stent Group and 83 ± 31 mm in the Deferred Stent Group (P = 0.22). In the Deferred Stent Group, at the angiographic follow‐up, the dissection length was significantly shorter than at the index procedure (40 ± 35 mm versus 83 ± 31 mm, P <0.001). The total stent length was significantly shorter in the Deferred Stent Group versus the Elective Stent Group (22 ± 33 mm versus 56 ± 28 mm; P < 0.001). At six‐month follow‐up, rate of cardiac death and myocardial infarction (6.7% vs 0; P = 0.049) and of stent thrombosis (5% vs 0%; P = 0.10) were higher in the Elective Stent Group. The present study suggests that deferring stenting implantation following STAR recanalization (1) limits the stent length and (2) is associated with a lower rate of objective endpoints. © 2014 Wiley Periodicals, Inc.     

A new technique for shortening a guiding catheter during retrograde recanalization of a chronic total occlusion

This report introduces successful retrograde angioplasty of chronic total occlusion with a long collateral channel using a new technique of shortening the guiding catheter. With this method, we secured the lengths of the guidewire and the microcatheter for retrograde intervention without sacrificing the position of the tracked guidewire. © 2010 Wiley‐Liss, Inc.